Advertisement
Canada markets open in 1 hour 31 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7313
    +0.0016 (+0.22%)
     

  • CRUDE OIL

    82.93
    +0.12 (+0.14%)
     

  • Bitcoin CAD

    87,301.05
    -3,681.24 (-4.05%)
     

  • CMC Crypto 200

    1,358.01
    -24.56 (-1.78%)
     

  • GOLD FUTURES

    2,341.80
    +3.40 (+0.15%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,495.25
    -169.25 (-0.96%)
     

  • VOLATILITY

    16.23
    +0.26 (+1.63%)
     

  • FTSE

    8,094.62
    +54.24 (+0.67%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6822
    +0.0003 (+0.04%)
     

Midday movers: Abercrombie & Fitch, Petco Health, Palo Alto Networks and more

Investing.com
·1 min read

Investing.com -- Stocks are falling on Wednesday as negotiations on the debt ceiling dragged on with the deadline swiftly approaching. Here are the market movers for May 24.

Abercrombie&Fitch Company (NYSE:ANF) shares jumped 27% as the specialty retailer reported a surprise profit for the first quarter and a gain in net sales, led by its namesake brand amid a reinvention. Shares of fellow retailer Kohl’s Corp (NYSE:KSS), which operates department stores, also jumped 7.7% after a surprise profit. Petco Health and Wellness Company Inc (NASDAQ:WOOF) shares fell 15% after the pet supply retailer provided weak revenue guidance for the current quarter. It beat expectations for the first quarter. Palo Alto Networks Inc (NASDAQ:PANW) shares rose 7.4% after the cybersecurity firm raised its guidance for profit, sales and billings for the fiscal year. Its third-quarter adjusted profit beat expectations. Intuit Inc (NASDAQ:INTU) shares fell 6.9% after the maker of financial software such as TurboTax reported third-quarter revenue below forecasts. While it raised its outlook for the full fiscal year, it gave a fourth-quarter profit estimate that fell short of expectations.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares slid 11% after the biotech said the Food and Drug Administration was pushing back a decision date on its muscular dystrophy gene therapy by about a month.

Related Articles

Biden administration urges Supreme Court not to hear Apple-Caltech patent case

JPMorgan can sue former executive Staley over Epstein ties -US judge